As it begins Phase IIa clinical trials, Mesoblast is riding high: its share price is climbing, its market capitalisation is booming and all that promise seems to be coming good.

With AusBiotech 2007 being held in Brisbane next week, ALS takes its bi-annual survey of the state of the industry.

$331 million deal sees Roche move into RNAi-based therapeutics.

PolyNovo Biomaterials, jointly owned by CSIRO and Xceed Biotechnology (ASX:XBL) has signed a partnering and licensing agreement potentially worth more than AUD$11 million with giant US-based device maker Medtronic.